News
CSCI
3.290
+5.79%
0.180
COSCIENS Biopharma Advances Avenanthramide Clinical Trial To Phase 2a For Inflammation Treatment
NASDAQ · 1d ago
COSCIENS Initiates Phase 2a Clinical Efficacy Study Of Avenanthramides Product Being Developed For Potential Applications In Managing Conditions Related To Inflammation
Benzinga · 1d ago
COSCIENS BIOPHARMA INC. ANNOUNCES SUCCESSFUL PHASE 1 RESULTS SUPPORTING INITIATION OF PHASE 2A CLINICAL EFFICACY TRIAL WITH AVENANTHRAMIDES AS A POTENTIAL ANTI-INFLAMMATORY PRODUCT
Reuters · 1d ago
Weekly Report: what happened at CSCI last week (0303-0307)?
Weekly Report · 4d ago
HP Enterprise's outlook dims on tariffs, 'aggressive competitive pricing'
Seeking Alpha · 03/07 14:31
Weekly Report: what happened at CSCI last week (0224-0228)?
Weekly Report · 03/03 11:00
Weekly Report: what happened at CSCI last week (0217-0221)?
Weekly Report · 02/24 11:00
Weekly Report: what happened at CSCI last week (0210-0214)?
Weekly Report · 02/17 10:58
Weekly Report: what happened at CSCI last week (0203-0207)?
Weekly Report · 02/10 10:53
Weekly Report: what happened at CSCI last week (0127-0131)?
Weekly Report · 02/03 10:56
Weekly Report: what happened at CSCI last week (0120-0124)?
Weekly Report · 01/27 10:59
Weekly Report: what happened at CSCI last week (0113-0117)?
Weekly Report · 01/20 10:52
Weekly Report: what happened at CSCI last week (0106-0110)?
Weekly Report · 01/13 10:53
Weekly Report: what happened at CSCI last week (1230-0103)?
Weekly Report · 01/06 10:59
Weekly Report: what happened at CSCI last week (1223-1227)?
Weekly Report · 12/30/2024 10:54
COSCIENS Biopharma halts investment in macimorelin; CMO to depart
Seeking Alpha · 12/23/2024 13:49
COSCIENS Biopharma Focuses on Natural Product Growth
TipRanks · 12/23/2024 13:07
Cosciens Biopharma provides update, reiterates pipeline prioritization
TipRanks · 12/23/2024 12:50
COSCIENS Biopharma Shifts Focus to Natural-Based Products for Health & Wellness
Benzinga · 12/23/2024 12:46
COSCIENS BIOPHARMA INC. PROVIDES CORPORATE UPDATE AND HIGHLIGHTS PIPELINE PRIORITIZATION
Reuters · 12/23/2024 12:45
More
Webull provides a variety of real-time CSCI stock news. You can receive the latest news about Cosciens Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About CSCI
More
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.